La vendita allo scoperto per Nutriband dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Nutriband. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Nutriband (NASDAQ:NTRB) Azioni, Report sulle vendite allo scoperto

Nutriband

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Nutriband Inc

WIIM

Tapestry shares are trading higher after the company announced agreements for a $2 billion Accelerated Share Repurchase program.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">43.94</td>
<td align="right">0.18</td>
<td align="right">0.41</td>
<td>2.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">82.21</td>
<td align="right">0.32</td>
<td align="right">0.39</td>
<td>14.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">144.40</td>
<td align="right">0.37</td>
<td align="right">0.25</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">215.27</td>
<td align="right">0.27</td>
<td align="right">0.12</td>
<td>183</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.22</td>
<td align="right">0.05</td>
<td align="right">0.09</td>
<td>234.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">97.00</td>
<td align="right">-0.12</td>
<td align="right">-0.13</td>
<td>9.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.06</td>
<td align="right">-0.03</td>
<td align="right">-0.04</td>
<td>858</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">233.43</td>
<td align="right">-0.05</td>
<td align="right">-0.03</td>
<td>21.7K</td>
</tr>
</tbody>
</table>
<p><a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. </p>
<p><em>For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.</em> </p>


Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For November 22, 2024

<p>Targeting $200B Digital Grocery Market With Key Retailers Like Fareway Stores And Vroom Delivery</p>


News

PUBM

PubMatic Partners With DIGITS Agency To Monetize Digital Grocery Advertising Through Scalable AdTech Platform

<p>Wells Fargo  analyst Gary Mobley   initiates coverage on Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Overweight rating and announces Price Target of $23.</p>


Price Target

Initiation

Analyst Ratings

ALGM

Wells Fargo Initiates Coverage On Allegro Microsystems with Overweight Rating, Announces Price Target of $23

<p>Leerink Partners  analyst Jeffrey La Rosa   initiates coverage on Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) with a Outperform rating and announces Price Target of $79.</p>


JANX

Leerink Partners Initiates Coverage On Janux Therapeutics with Outperform Rating, Announces Price Target of $79

<p>Keybanc  analyst Tim Rezvan   maintains Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) with a Overweight and raises the price target from $165 to $205.</p>


GPOR

Keybanc Maintains Overweight on Gulfport Energy, Raises Price Target to $205

APTO

Aptose Biosciences shares are trading lower after the company announced the pricing of an $8 million public offering.

Offerings

Aptose Biosciences Prices $8M Public Offering Of 40M Shares And 20M Warrants At $0.20 Per Unit; Warrants Priced At $0.25 Per Share And Expire In Five Years, With Closing Expected On November 25, 2024

<p>Goldman Sachs  analyst Adam Bubes   initiates coverage on AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Buy rating and announces Price Target of $130.</p>


Goldman Sachs Initiates Coverage On AECOM with Buy Rating, Announces Price Target of $130

<p>Wells Fargo  analyst Joe Quatrochi   initiates coverage on ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight rating and announces Price Target of $155.</p>


Wells Fargo Initiates Coverage On ARM Holdings with Overweight Rating, Announces Price Target of $155

SBFM

Sunshine Biopharma shares are trading higher after its Nora Pharma subsidiary launched Ursodiol, a generic version of URSO DS.

<p>Keybanc  analyst Steve Barger   maintains AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) with a Overweight and raises the price target from $205 to $215.</p>


Keybanc Maintains Overweight on AMETEK, Raises Price Target to $215

<p>Confirmed By Nasdaq Listing Qualifications On November 21, 2024</p>


NDRA

ENDRA Life Sciences Regains Compliance With Nasdaq Minimum Bid Price Rule

Sunshine Biopharma's Nora Pharma Subsidiary Launches Ursodiol, A Generic Version Of URSO DS

<p>Goldman Sachs  analyst Adam Bubes   initiates coverage on EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Sell rating and announces Price Target of $445.</p>


Goldman Sachs Initiates Coverage On EMCOR Group with Sell Rating, Announces Price Target of $445

<p>UBS  analyst David Vogt   initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Neutral rating and announces Price Target of $95.</p>


UBS Initiates Coverage On Celestica with Neutral Rating, Announces Price Target of $95

<p>Goldman Sachs  analyst Ben Andrews   initiates coverage on Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announces Price Target of $320.</p>


FLUT

Goldman Sachs Initiates Coverage On Flutter Entertainment with Buy Rating, Announces Price Target of $320

Nano Labs Unveils Second-Generation V Series Crypto Mining Products With 5x Power Efficiency Boost And Enhanced Stability, Featuring Advanced Cuckoo 3.0 Chips In V2, V2H, And V2X Models

Applied Industrial Technologies To Acquire Hydradyne, Terms Not Disclosed; Applied Expects The Acquisition To Contribute Approximately $260M In Sales And $30M In EBITDA Before Anticipated Synergies

Johnson & Johnson Submits Supplemental Biologics License Application To FDA Seeking Approval Of Subcutaneous Induction Regimen Of TREMFYA

Nutriband stock climbs on receiving first order for sports brand licensee Fit for Life Group

Nutriband signs exclusive supplier agreement with Fit for Life

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Nutriband</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ntrb-stock-quote/"><strong>NTRB</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Nutriband reported earnings per share of -23 cents.</li><li>The company reported revenue of $524,613.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/ntrb-stock-earnings-nutriband-for-q4-of-2023/">NTRB Stock Earnings: Nutriband Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

NTRB Stock Earnings: Nutriband Reported Results for Q4 2023

NTRB, AERT and SPWR among mid-day movers

GoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare movers

Nutriband Inc (NTRB) has shared an announcement. Sergei Glinka, with a wealth of experience in the commercial sector, has been appointed as a new d...

Nutriband Inc Bolsters Board with Experienced Commercial Director

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Nutriband</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ntrb-stock-quote/"><strong>NTRB</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Nutriband reported earnings per share of -21 cents.</li><li>The company reported revenue of $408,532.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/06/ntrb-stock-earnings-nutriband-for-q1-of-2024/">NTRB Stock Earnings: Nutriband Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

NTRB Stock Earnings: Nutriband Reported Results for Q1 2024

An update from Nutriband ( ($NTRB) ) is now available. Nutriband Inc. has unveiled a plan to repurchase up to $1 million of its own common stock, s...

Nutriband Announces Stock Buyback and Advances in Fentanyl Patch Development

It seems time for the Securities and Exchange Commission to oversee stock advertising and consider a ban, or at least a danger warning label.

Are Pharma Stocks Harmful To Your Financial Health ?

Nutriband ( ($NTRB) ) has issued an announcement. Nutriband Inc. has secured a full patent from the Chinese National Intellectual Property Administ...

Nutriband Secures Chinese Patent for AVERSA™ Technology

AERT

ATNF

BIAF

CELC

CELZ

CLVR

EYEN

GDRX

INVO

NTRB

OMER

SEEL

SPWR

Press Releases

Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology

Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25

Earnings

Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

Nutriband Inc. Authorizes $1M Share Buyback Program

Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology

Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17

Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica

Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application

Comments

Nutriband

Vendite allo scoperto

Nutriband (NASDAQ:NTRB) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO